Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 15.3%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 2,050,094 shares, a decline of 15.3% from the January 29th total of 2,419,408 shares. Approximately 5.5% of the shares of the company are short sold. Based on an average daily trading volume, of 329,823 shares, the days-to-cover ratio is currently 6.2 days. Based on an average daily trading volume, of 329,823 shares, the days-to-cover ratio is currently 6.2 days. Approximately 5.5% of the shares of the company are short sold.

Insider Activity

In other news, Director Luke Evnin sold 108,606 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $0.61, for a total transaction of $66,249.66. Following the completion of the transaction, the director directly owned 2,550,674 shares of the company’s stock, valued at approximately $1,555,911.14. This trade represents a 4.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 908,418 shares of company stock valued at $651,121. Corporate insiders own 23.60% of the company’s stock.

Hedge Funds Weigh In On Werewolf Therapeutics

Large investors have recently modified their holdings of the stock. Quadrature Capital Ltd bought a new stake in shares of Werewolf Therapeutics during the second quarter valued at approximately $28,000. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics during the 2nd quarter worth $48,000. Regal Investment Advisors LLC lifted its holdings in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. boosted its position in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after buying an additional 24,003 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of Werewolf Therapeutics in the 1st quarter valued at $79,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on HOWL. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, January 21st. Citigroup cut Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Citizens Jmp cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Finally, HC Wainwright dropped their price objective on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.75.

Werewolf Therapeutics Price Performance

Shares of HOWL stock traded down $0.02 during trading hours on Thursday, hitting $0.59. 150,320 shares of the company’s stock were exchanged, compared to its average volume of 459,187. Werewolf Therapeutics has a 52 week low of $0.53 and a 52 week high of $2.38. The stock has a market cap of $28.71 million, a price-to-earnings ratio of -0.37 and a beta of 0.78. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. The stock’s 50-day moving average is $0.64 and its 200-day moving average is $1.09.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.